Cilastatin, a new therapeutic promise for acute kidney injury.

Acute Kidney Injury / drug therapy Humans Cilastatin / therapeutic use Animals Kidney Tubules, Proximal / drug effects Nanoparticles

Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
Oct 2024
Historique:
received: 30 06 2024
revised: 16 07 2024
accepted: 24 07 2024
medline: 21 9 2024
pubmed: 21 9 2024
entrez: 20 9 2024
Statut: ppublish

Résumé

Acute kidney injury is a devasting clinical syndrome resulting from multiple causes, characterized by an abrupt deterioration of kidney function for which there is no pharmacologic treatment. Cilastatin has demonstrated direct nephroprotective effects in acute kidney injury and now is shown to be effective to specifically target therapeutically loaded nanoparticles to the proximal tubule to treat acute kidney injury.

Identifiants

DOI: 10.1016/j.kint.2024.07.024 PMID: 39304269
pubmed: 39304269
pii: S0085-2538(24)00553-2
doi: 10.1016/j.kint.2024.07.024
pii:
doi:

Substances chimiques

Cilastatin 141A6AMN38

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

560-562

Informations de copyright

Copyright © 2024 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Auteurs

María Ángeles González-Nicolás (MÁ)

Renal Physiopathology Laboratory, Department of Nephrology, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Department of Physiology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain; RICORS2040, Madrid, Spain.

Alberto Lázaro (A)

Renal Physiopathology Laboratory, Department of Nephrology, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Department of Physiology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain; RICORS2040, Madrid, Spain. Electronic address: alberlaz@ucm.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Maladies du rein › Insuffisance rénale › Atteinte rénale aigüe › Cilastatin, a new therapeutic promise for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cilastatin, a new therapeutic promise for...
questionsmedicales.fr › Lipides › Acides gras › Acides gras insaturés › Acides gras monoinsaturés › Cilastatine › Cilastatin, a new therapeutic promise for...
questionsmedicales.fr › Eucaryotes › Animaux › Cilastatin, a new therapeutic promise for...
questionsmedicales.fr › Appareil urogénital › Voies urinaires › Rein › Néphrons › Tubules rénaux › Tubules contournés proximaux › Cilastatin, a new therapeutic promise for...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › Cilastatin, a new therapeutic promise for...